---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-26-000008"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T05:57:43.982505+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Akebia leases 43,474 sq ft in Waltham for HQ; amends CEO/CFO severance

## Summary
- Leases 28,518 sq ft office + 14,956 sq ft lab at 180 Third Ave, Waltham, MA; HQ relocation planned for Sept 2026.
- Annual office rent starts at $898,317, lab rent at $1,046,920; initial 84-month term with 5-year renewal option.
- Security deposit of $810,515 in irrevocable letter of credit; landlord pays all work costs.
- CEO John Butler severance: 12 months salary (non-CIC) or 24 months salary + 200% bonus (CIC); full equity vest on CIC.
- CFO Erik Ostrowski severance: 12 months salary (non-CIC) or 12 months salary + 100% bonus (CIC); full vest of pre-2026 grants on CIC.

## SEC filing metadata
- accession: 0001517022-26-000008
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000008/0001517022-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000008/akba-20260127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-26-000008
- JSON: https://secwatch.observer/filing/0001517022-26-000008.json
- Plain text: https://secwatch.observer/filing/0001517022-26-000008.txt

## Key facts
- Material Agreements
  Akebia Therapeutics, Inc. entered into Lease Agreement with BP THIRD AVENUE LLC valued at Annual rent for Office Premises initially $898,317, for Lab Premises initially $1,046,920, with rent (effective 2026-01-27).
  - Action: entry
  - Agreement: lease
  - Counterparty: BP THIRD AVENUE LLC
  - Value: Annual rent for Office Premises initially $898,317, for Lab Premises initially $1,046,920, with rent
  - Effective: 2026-01-27
  source text: On January 27, 2026, Akebia Therapeutics, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with BP THIRD AVENUE LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company will lease an aggregate of approximately 43,474 square feet, consisting of 28,518 square feet of office space (the “Office Premises”) and 14,956 square feet of laboratory space (the “Lab Premises”) located at the building commonly known as 180 CityPoint and numbered 180 Third Avenue, Waltham, Massachusetts 02451
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000008/0001517022-26-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.